Dr Huzaifa Khorakiwala, Executive Director of Wockhardt Limited, on Saturday said that the fall of US reciprocal tariffs on Indian pharmaceutical products will pose a significant challenge to the industry.
The Indian Pharmaceutical Alliance (IPA) on Thursday welcomed the exclusion of pharmaceuticals from US tariffs, with Secretary General Sudarshan Jain emphasising the deepening of India-US trade ties under the Mission 500 initiative, aiming to double bilateral trade to USD 500 billion.
Pune (Maharashtra) [India], March 11: India can develop indigenous low-cost medical equipment, molecules and therapies and give it to the world, opined. India has the potential to show the way to the world in diabetes treatment, said Dr. V. Mohan, President and Director of the Madras Diabete
Indian pharma companies like CDMOs (Contract Development and Manufacturing Organizations) will not see major disruptions from the proposed US tariffs of 10-25 per cent, according to a report by B&K Securities.
Mumbai (Maharashtra) [India], February 25: The Indian Pharmaceutical Alliance (IPA) will host the 10th Global Pharmaceutical Quality Summit (GPQS) on February 27-28, 2025, at the J.W. Marriott Juhu in Mumbai. With the theme "Navigating the Next Decade for Global Excellence", the summit will
Some Indian CDMOs have witnessed a 50 per cent year-on-year increase in Requests for Proposals (RFPs) in 2024, as global pharmaceutical companies look to diversify supply chains beyond China. Indian pharma services are priced 20 per cent lower than their Chinese counterparts, making them a c
Union Minister of State for Health and Family Welfare, Anupriya Patel, delivered the keynote address at the 15th International Meeting of World Pharmacopoeias (IMWP), hosted by the Indian Pharmacopoeia Commission (IPC) under the Ministry of Health and Family Welfare, Government of India, in
The Indian pharmaceutical and healthcare industry has high expectations from the upcoming Union Budget 2025, according to a report by CareEdge Ratings. The sector is calling for increased government support to strengthen infrastructure and drive innovation.
As the US remains the top market for the Indian Pharmaceutical industry, now after the new US government under the leadership of Donald Trump as the President, experts in India are expecting opportunities for collaboration in healthcare security and affordability.
Strong pricing growth (+5.3 per cent YoY) and the launch of new products from recent patent expiries (+2.6 per cent YoY) have continued to drive overall market performance.